The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. ##STR00001##

The present invention relates to novel aminobisphosphonate compounds useful as antiwear and/or friction modifier additive components, lubricant additive compositions and lubricant compositions each comprising such compounds, and methods for making and using the same.

The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.

The present invention features compounds effective in inhibiting active against Hepatitis C virus (HCV) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

A process for the preparation of fluorinated compounds having at least one OSF.sub.5 group, said method comprising the step of reacting SOF.sub.4 with a fluorinated 3- or 4-membered cyclic ether in the presence of a fluoride catalyst.

The present invention relates to a method for preparing a tris(trialkylsilyl)phosphine in high yield and high purity with safety and no risk of fire or explosion.

Universally usable process for reducing the chlorine content of organotetraphosphites.

A silicon-containing polymer is represented by the general formula: (I) wherein A, Q, Z, x, and y are as defined in the specification, and I is iodine. Group Q includes a hydrolyzable silane group and group A is fluorinated. A method of making the silicon-containing polymer is also disclosed.

A phosphinimide catalyst system comprises: i) a phosphinimide pre-polymerization catalyst having a cyclopentadienyl ligand and a phosphinimide ligand which is substituted with a guanidinate type group; and ii) a catalyst activator. The catalyst system polymerizes ethylene with an alpha-olefin to give high molecular weight ethylene copolymer.

The present invention relates to inorganic-organic hybrid compounds for use in medicine or for use as medication, consisting of an inorganic metal cation and an organic platinum-containing cytostatic anion, in particular also a cisplatin derivative.